Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Integrated workflow for rapid selection and optimization of hybridoma cell lines

Hybridomas are comprised of the fusion between B-cell splenocytes from antigen-immunized mice and a myeloma tumor cell line result in immortalized antibody-producing clonal cell lines that can be screened for antigen-specific binding. Today, more than half of the commercialized antibody drugs are from hybridoma cell lines, and hybrid hybridomas have been used to produce bispecific monoclonal antibodies. Screening a hybridoma fusion and then subcloning candidate hybrids are time-consuming elements of the monoclonal antibody discovery process (Figure 1).

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Most Popular

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register